Advise Connect Inspire (ACI) helps international life sciences startups and emerging companies with their U.S. market entry. 

This high-end life sciences consulting firm runs programs for governments, accelerators, and industry organizations but also offers support directly to companies that seek access to the prime global life sciences innovation hub. 

We are based in the heart of Kendall Square and have access to talent and to a vast network of industry leaders, investors, and other relevant stakeholders.

Our team of experienced industry leaders has a proven track-record of helping companies succeed.

We are convinced that the complexity of building and growing a life sciences company calls for programs that are flexible and built around the needs of each company. 

We also understand the unique challenges of international companies that are trying to navigate a new ecosystem, and we know how to best help them.

If you would like to learn more about us and how we can help you, please contact us to set up a meeting or a conference call.

In fall of 2015, Christoph was appointed by the German Ministry for Economy to lead the build out of the German Accelerator Life Sciences (GALS) in Cambridge, MA. The GALS team provides high-end consulting to young German biotechs and supports them with introducing their products to the US market.

Christoph is Venture Partner at Third Rock Ventures and focuses there on the formation of new companies that discover and develop novel therapeutic approaches.

Christoph is also Executive Vice President at Blueprint Medicines (BPMC). For the last five years, as CSO & Chief Drug Hunter, Christoph helped guide Blueprint from raising series A funding to its initial public offering. He has a proven record in cancer drug discovery, including contributing to more than 25 drugs that reached first-in-human clinical trials and four approved medicines.

Christoph joined Blueprint Medicines from Sanofi, where he was Vice President and Global Head of Oncology Drug Discovery & Preclinical Development. Before joining Sanofi, he was Executive Director and Senior Unit Head of Oncology Discovery at the Novartis Institutes for Biomedical Research (NIBR). Prior to Novartis, Christoph was an Associate Professor at the Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University School of Medicine in Baltimore, MD. Christoph discovered that all cancers are genetically unstable and was involved in the identification of several cancer driver genes, incl. BRAF and PIK3CA. He has authored more than hundred scientific articles published in top-tier scientific journals, including Cell, Nature, and Science. Christoph studied human genetics in Salzburg, Austria, and received his Ph.D. from the University of Heidelberg and his MBA with a focus on medical services management from the Johns Hopkins Carey Business School.

Christoph holds Adjunct Associate Professor positions at Johns Hopkins University and Harvard University. He has received numerous awards including the Boveri Award in Cancer Genetics, the Benjamin Baker Scholar award, and a V Foundation scholarship.

Christoph was awarded the Novartis Oncology President’s Award for top innovator and has been elected to membership in the Johns Hopkins Society of Scholars.

He is a strong and outspoken advocate of patients’ rights and is featured in the New York Times bestseller and HBO movie “The Immortal Life of Henrietta Lacks.”   

Please contact us if you are interested in joining ACI.